Affiliation:
1. Department of Hematology All India Institute of Medical Sciences (AIIMS) New Delhi India
2. Department of Clinical Hematology Christian Medical College and Hospital Ludhiana Punjab India
3. Department of Haematology NRS Medical College Kolkata India
4. Department of Clinical Hematology Seth GSM and KEM Hospital Mumbai India
5. Department of Clinical Hematology King George's Medical University Lucknow Uttar Pradesh India
6. Department of Pediatric Hematology & Oncology Post Graduate Institute of Child Health Noida India
7. Department of Hematology NRS Medical College and Hospital Kolkata India
Abstract
AbstractIntroductionEmicizumab is the initial subcutaneously administered bispecific antibody approved as a prophylactic treatment for patients with haemophilia A (PwHA).AimThis study assessed the economic evaluation of emicizumab treatment for non‐inhibitor severe haemophilia A (HA) patients in India.MethodsA Markov model evaluated the cost‐effectiveness of emicizumab prophylaxis compared to on‐demand therapy (ODT), low‐dose prophylaxis (LDP; 1565 IU/kg/year), intermediate‐dose prophylaxis (IDP; 3915 IU/kg/year) and high‐dose prophylaxis (HDP; 7125 IU/kg/year) for HA patients without factor VIII inhibitors. Inputs from HAVEN‐1 and HAVEN‐3 trials included transition probabilities of different bleeding types. Costs and benefits were discounted at a 3.5% annual rate.ResultsIn the base‐case analysis, emicizumab was cost‐effective compared to HDP, with an incremental cost‐effectiveness ratio (ICER) per quality‐adjusted life‐years (QALY) of Indian rupees (INR) 27,869. Compared to IDP, ODT and LDP, emicizumab prophylaxis could be considered a cost‐effective option if the paying threshold is >1 per capita gross domestic product (GDP) with ICER/QALY values of INR 264,592, INR 255,876 and INR 305,398, respectively. One‐way sensitivity analysis (OWSA) highlighted emicizumab cost as the parameter with the greatest impact on ICERs. Probabilistic sensitivity analysis (PSA) indicated that emicizumab had a 94.7% and 49.4% probability of being cost‐effective at willingness‐to‐pay (WTP) thresholds of three and two‐times per capita GDP.ConclusionEmicizumab prophylaxis is cost‐effective compared to HDP and provides value for money compared to ODT, IDP, and LDP for severe non‐inhibitor PwHA in India. Its long‐term humanistic, clinical and economic benefits outweigh alternative options, making it a valuable choice in resource‐constrained settings.
Subject
Genetics (clinical),Hematology,General Medicine
Reference39 articles.
1. World Federation of Hemophilia.Report on the Annual Global Survey 2021 ‐ eLearning Platform [Internet]. [cited 2023 Apr 28].Accessed on June17 2023.https://elearning.wfh.org/resource/report‐on‐the‐annual‐global‐survey‐2021
2. Hemophilia Federation India.Annual Report 2017–2018. Accessed on June 17 2023.AR 2018.cdr (hemophilia.in).
3. Haemophilia in the Indian Scenario
4. World Federation of Hemophilia.Severity of hemophilia. Accessed 22 October 2021.https://www.wfh.org/en/page.aspx?pid=643
5. Patient-reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (P-FiQ) study
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献